Cencora

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Here's Why You Should Hold Cencora Stock in Your Portfolio for Now

AI-generated analysis

πŸ“ˆ Zacks Investment Research assigns Cencora a Rank #3 (Hold) after shares gained 18.9% in the past six months versus 0.4% industry growth.

πŸš€ Management raised fiscal 2026 guidance to expect 7-9% revenue growth and 11.5–13.5% operating income growth driven by U.S. segment strength.

πŸ’Š The OneOncology acquisition enhances vertical integration into high-margin MSOs, shifting the company toward differentiated service-oriented revenue streams.

πŸ›‘οΈ Cencora maintained gross profit dollars despite regulatory list price reductions through successful contract renegotiations with manufacturers.

⚠️ International Healthcare Solutions operating income declined 14% due to timing-related pricing adjustments in certain markets.

πŸ“‰ The company faces headwinds from customer losses, including the exit of a large oncology customer acquired by a competitor.

πŸ”„ Acquisitions like OneOncology are expected to be EPS-neutral in the first 12 months due to integration complexity and limited immediate earnings accretion.

πŸ“‰ Cencora has witnessed a negative estimate revision trend, with the Zacks Consensus Estimate for fiscal 2026 earnings decreasing to $17.59 per share.

πŸ” Analysts highlight execution risks in aligning physician networks and systems while scaling the MSO footprint across multiple specialties.

πŸ“Š Peer comparison shows Cardinal Health (CAH) rallied 45% over six months, while Cencora's long-term growth is anticipated to improve 12.2%.

Bullish Signals
  • Cencora shares have gained 18.9% in the past six months compared to the industry's 0.4% growth and the S&P 500's 1.8% gain.
  • Management raised fiscal 2026 guidance, now expecting 7-9% revenue growth and 11.5–13.5% operating income growth driven by continued strength in the U.S. segment.
  • U.S. Healthcare Solutions operating income growth guidance was notably increased to 14-16%, reflecting strong execution despite customer losses.
  • The company demonstrated resilience in pricing dynamics, maintaining gross profit dollars despite list price reductions tied to regulatory changes through successful contract renegotiations.
  • Expansion into pharmaceutical-centric MSOs, particularly through the OneOncology acquisition, enhances vertical integration and provides high-margin revenue streams.
  • Cencora's bottom line is anticipated to improve 12.2% over the next five years with earnings beating estimates in each of the trailing four quarters.
Risk Factors
  • The International Healthcare Solutions segment reported a 14% decline in operating income primarily due to timing-related pricing adjustments in certain markets.
  • Cencora continues to face headwinds from customer losses, including the exit of a large oncology customer due to acquisition by a competitor.
  • Analysts note integration risks and limited near-term EPS contribution from acquisitions, with OneOncology expected to be EPS-neutral in the first 12 months.
  • Cencora has been witnessing a negative estimate revision trend for fiscal 2026, with the consensus earnings per share decreasing by 1 cent to $17.59.
  • The exit of large distribution contracts due to customer consolidation underscores exposure to healthcare provider consolidation and potential revenue stream instability.
Full Analysis
Cencora (COR) is recommended for holding by Zacks Investment Research, which assigns it a Rank #3. The company has outperformed its industry and the S&P 500 over the past six months, gaining 18.9% compared to minimal industry growth. As one of the world's largest pharmaceutical service companies, Cencora focuses on drug distribution and related services to reduce healthcare costs and improve patient outcomes. The company is strengthening its position through vertical integration into high-margin Medical Specialty Organizations (MSOs), specifically via the OneOncology acquisition. Management has raised its fiscal 2026 guidance, projecting 7-9% revenue growth and 11.5–13.5% operating income growth. Specifically, U.S. Healthcare Solutions operating income growth was upgraded to 14-16%, reflecting strong execution despite customer losses. Cencora demonstrated resilience in pricing dynamics, maintaining gross profit dollars despite regulatory-driven list price reductions through successful contract renegotiations. However, the company faces risks including a 14% decline in international segment operating income due to timing-related pricing adjustments and ongoing headwinds from customer losses, such as the exit of a large oncology client. Analysts note integration risks associated with MSO acquisitions, which are expected to be EPS-neutral in the first 12 months. Additionally, Cencora has seen a negative trend in analyst estimate revisions for fiscal 2026, with consensus earnings per share decreasing slightly. The article concludes by comparing Cencora's performance and growth estimates against peers like Intuitive Surgical, Align Technology, and Cardinal Health.